Tuscan Ridge Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tuscan Ridge Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,000	Closed	-$490K	–	636
2019 Q3	$490K	Hold	5,000	–	–	0.03%	512
2019 Q2	$655K	Buy	5,000 +1,000	+25%	+$129K	0.05%	455
2019 Q1	$541K	Buy	+4,000	New	+$497K	0.04%	439

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tuscan Ridge Asset Management's ALXN Position: Q4 2019 in Review

Tuscan Ridge Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 3,900 shares — an estimated $382K sold.

Tuscan Ridge Asset Management first reported a position in ALXN in Q2 2019 and held it in 2 quarters. The position peaked at $382K in Q3 2019. 668 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

Tuscan Ridge Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Tuscan Ridge Asset Management sold 3,900 Alexion Pharmaceuticals shares in Q4 2019, an estimated $382K.
Tuscan Ridge Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 2 quarters.
Tuscan Ridge Asset Management's Alexion Pharmaceuticals position peaked at $382K in Q3 2019.
668 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Tuscan Ridge Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.